# EDGAR Filing Document

**Accession Number:** 0001835579
**File Stem:** 0001140361-25-022073
**Filing Date:** 2025-6
**Character Count:** 3288
**Document Hash:** 1d6377140902a46287eede944f480a0e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-022073.hdr.sgml**: 20250822

**ACCESSION NUMBER**: 0001140361-25-022073

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250610

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ikena Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001835579
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** 857-343-8292

**MAIL ADDRESS:**
- **STREET 1:** 12526 HIGH BLUFF DRIVE
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ikena Oncology, Inc.
- **DATE OF NAME CHANGE:** 20201208

Ikena Oncology, Inc.

645 Summer Street, Suite 101

Boston, MA 02210

June 10, 2025

#### VIA EDGAR

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street NE

Washington, D.C. 20549-3628

Attention: Ms. Christine Torney Ms. Lynn Dicker Mr. Daniel Crawford Mr. Alan Campbell

---

| | |
|:---|:---|
| **Re:** | **Ikena Oncology, Inc.**<br> **Acceleration Request for Registration Statement on Form S-4**<br> **File No. 333-285881** |

---

---

| | |
|:---|:---|
| **Requested Date:** | **June 11, 2025** |
| **Requested Time:** | **4:15 p.m. Eastern Time** |

---

Dear Ms. Torney, Ms. Dicker, Mr. Crawford and Mr. Campbell:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "**Act**"), Ikena Oncology, Inc. (the "**Company**") hereby requests that the effective date of the above-referenced registration statement (the "**Registration Statement**") be accelerated to June 11, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Stephanie Richards at (617) 570-1927. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Stephanie Richards, by email to <u>srichards@goodwinlaw.com</u>.

If you have any questions regarding this request, please contact Stephanie Richards of Goodwin Procter LLP at (617) 570-1927.

---

| |
|:---|
| Sincerely, |
| Ikena Oncology, Inc. |
| /s/ Mark Manfredi |
| Mark Manfredi, Ph.D. |
| President and Chief Executive Officer |

---

---

| | |
|:---|:---|
| cc: | Stephanie Richards, *Goodwin Procter LLP*<br> John T. Haggerty, *Goodwin Procter LLP*<br> Richard A. Hoffman, *Goodwin Procter LLP*<br> Amanda Gill, *Goodwin Procter LLP*<br> Lauren Visek, *Goodwin Procter LLP* |

---

------